favourites: Micropep, ComeBack Mobility, Muna Therapeutics
Medorion Raises $6M in Funding
Medorion, a Tel Aviv, Israel-based developer of behavioral intelligence SaaS solutions for health insurers, completed a $6m funding round.
The round, which brought total funding to $9m, was led by 10D with participation from existing investors iAngels and TAU Ventures.
The company intends to use the funds to hire new people, boost the adoption of its behavioral intelligence SaaS platform among additional U.S. insurers, accelerate the development of new risk adjustment and member experience solutions, as well as expand its platform’s utilization beyond Medicare Advantage plans into other government markets.
Led by Asaf Kleinbort, co-founder and CEO, Medorion provides an AI-powered SaaS platform that analyzes claims and social determinants of health (SDOH) data to accurately pinpoint the underlying psychological, environmental, and economic drivers and barriers behind people’s health decisions. With Medorion, insurers can understand members’ needs and personalize and automate one-on-one member conversations at scale, facilitating proactive interactions that improve health delivery and financial outcomes.
Medorion Raises $6M in Funding
Medorion, a Tel Aviv, Israel-based developer of behavioral intelligence SaaS solutions for health insurers, completed a $6m funding round
MiNA Therapeutics Receives $15M Equity Investment from Eli Lilly and Company
MiNA Therapeutics Limited, a London, UK-based provider of small activating RNA therapeutics, received a $15m equity investment from Eli Lilly and Company.
The company intends to use the funds to advance and expand its internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.
Led by Robert Habib, CEO, MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a new class of medicines that can restore or boost normal function in patients’ cells. The company is advancing a proprietary pipeline of new medicines with an initial focus on cancer and genetic diseases, while collaborating with pharmaceutical companies to apply its technology platform across a broad range of therapeutic areas.
MiNA Therapeutics Receives $15M Equity Investment from Eli Lilly and Company
MiNA Therapeutics Limited, a London, UK-based provider of small activating RNA therapeutics, received a $15m equity investment from Eli Lilly and Company
Micropep Raises €8.5M in Series A Funding
Micropep, a Toulouse, France-based agricultural biotech company, raised €8.5M in Series A funding.
The round was led by Supernova Invest with participation from FMC Ventures, Sofinnova Partners and IRDI Capital Investissement. Romain Sautrau, Investment Director at Supernova Invest will join the Board of Directors and Sara Olson, Principal at FMC Ventures, along with Jean-Michel Petit, Investment Director at IRDI Capital Investissement will be joining as Observers to the Board.
The financing will be used to further develop proprietary discovery platform and progress pipeline targeting disease control and weed suppression.
Led by Thomas Laurent, Micropep provides an innovative discovery platform for the development of novel peptide-based biological products for agriculture. The company, spun out from Centre National de la Recherche Scientifique (CNRS) and Toulouse University in 2016, a centre of excellence for AgriTech, has developed proprietary technology to precisely enhance plant traits without altering DNA by spraying “miPEPs”, a unique family of natural peptides regulating plant microRNAs. Micropep is positioned to enter and transform the EUR 47 billion-plus market for pesticides, initially targeting $28 billion herbicides and fungicides markets in Americas and Europe.
Micropep Raises €8.5M in Series A Funding - FinSMEs
Micropep, a Toulouse, France-based agricultural biotech company, raised €8.5M in Series A funding
Viracoat Raises £2M in Funding
Viracoat, a UK-based company which makes in PPE mask that begins killing COVID-19 and other viruses on contact, raised £2M in funding.
The round was led by J.J. Richards & Sons Pty Ltd, an Australian, family owned and operated business that provides waste management service solutions throughout Australia and New Zealand.
The company intends to use the capital to fund the final stages of accreditation and conduct research activities.
A subsidiary of Viracorp Ltd, Viracoat was set up to develop and produce a PPE mask that begins killing COVID-19 and other viruses on contact. The new PPE product is undergoing final stages of accreditation testing in the biomedical facilities at Lancaster University. The product is planned be in production at scale by August 2021, through The MEL Group at Sudbury, Suffolk. International sales and distribution, which are prioritising hospital and healthcare workers, have been contracted and international pre-production orders are already being processed.
Viracoat Raises £2M in Funding
Viracoat, a UK-based company which makes in PPE mask that begins killing COVID-19 and other viruses on contact, raised £2M in funding
ComeBack Mobility Raises $1M in Seed Funding
ComeBack Mobility, an Ukrainian medtech startup, raised $1M in seed funding.
Backers included Ukrainian medtech investment fund Fison, Peter Chernyshov, the ex-CEO of the telecom KyivStar, the pharmaceutical company Farmak, and several angel investors from Ukraine, Belgium and the US.
Led by CEO Ilya Popov, ComeBack Mobility provides “Smart Crutch Tip” orthopedic devices that work together with an app, shared by a patient and a doctor. The technology allows electronic communication with the doctor and provides an overview of the patient’s walking recovery progress. Patients have crutch tips that work together with a smartphone app, where they have rehabilitation programs set by their doctors. The app helps patients to be regular with exercises and keeping the load on the injured leg under the set program while consistently receiving doctor’s recommendations. The medical professional has a web and/or mobile app that contains data about all his or her patients and makes it possible to remotely monitor how the patient loads the injured leg, addressing the patient’s concerns, and adapting the program to their needs.
ComeBack Mobility Raises $1M in Seed Funding - FinSMEs
ComeBack Mobility, an Ukrainian medtech startup, raised $1M in seed funding
Kuano.ai Raises £1M in Seed Funding
Kuano.ai, a London, UK-based provider of a software platform for quantum modelling of enzymes, raised £1m in seed funding.
Backers included ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors.
The company intends to use the funds to expand the technology team and further develop its platform and asset development, including its own range of novel therapeutics and creating a data bank for use in its work with academic and commercial partners.
Led by Dr. Vid Stojevic, Co-Founder CEO, Kuano combines quantum physics, artificial intelligence (AI) and medicinal chemistry to discover therapeutics focused on enzyme inhibition. The company is using its platform to advance its own pipeline of novel therapeutics targeting unmet medical needs, as well as in collaborative programs with leading academic and commercial partners. This includes a recent research collaboration with Alzheimer’s Research UK University College London Drug Discovery Institute to identify inhibitors for treating degenerative neurological disorders.
Kuano.ai Raises £1M in Seed Funding - FinSMEs
Kuano.ai, a London, UK-based provider of a software platform for quantum modelling of enzymes, raised £1m in seed funding
Muna Therapeutics Raises US$73M in Series A Funding
Muna Therapeutics, a Copenhagen, Denmark-based biopharmaceutical company, raised US$73M in Series A funding.
The round was led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB.
The company intends to use the funds to advance small molecule programs focused on repairing neuronal dysfunction, resolving neuroinflammation and restoring neuroprotection and resilience to disease to Investigational New Drug (IND) applications.
Founded in 2020 by progranulin pathway thought leader Professor Simon Glerup and his team from Aarhus University, Denmark, in collaboration with Novo Seeds, the early-stage investment team of Novo Holdings, Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s.
Muna Therapeutics Raises US$73M in Series A Funding
Muna Therapeutics, a Copenhagen, Denmark-based biopharmaceutical company, raised US$73M in Series A funding
BillionToOne Closes $55M Series B Funding
BillionToOne, Inc., a Menlo Park, Calif.-based molecular diagnostics company, closed a $55m Series B funding round.
The round, announced in June 2021, was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.
The company is using the funds to expand its the clinical lab, as well as its commercial team nationwide.
Co-founded by Oguzhan Atay, Ph.D. and David Tsao, Ph.D., and also led by Jennifer Hoskovec, MS, CGC, Director of Medical Affairs, BillionToOne is a precision diagnostics company whose its patent-pending QCT molecular counter platform can count DNA molecules at the single-count level. Its flagship product, UNITY, is a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood.
BillionToOne Closes $55M Series B Funding - FinSMEs
BillionToOne, Inc., a Menlo Park, Calif.-based molecular diagnostics company, closed a $55m Series B funding round
Linus Health Raises $55M in Series B Funding
Linus Health, a Boston, MA-based digital health company focused on improving brain health, raised $55m in Series B funding.
The backers were not disclosed.
The company intends to use the funds to grow its team and accelerate development of its platform.
Led by David Bates, CEO, and Alvaro Pascual-Leone, co-founder, and a behavioral neurologist, neuroscientist, and Professor of Neurology at Harvard Medical School, Linus deploys technologies to promote overall health and mental acuity. Linus’s multimodal, smartphone- or tablet-based brain health solution collects objective data from multiple digital measures of cognitive and motor function (“digital biomarkers”) and translates this data into actionable insights. The solution allows care professionals to monitor brain health remotely, easily and conveniently over extended periods of time, even outside of clinical settings. Linus collects, aggregates and analyzes information drawn from data points like voice and speech patterns, visuospatial memory, dual-tasking ability and fine motor control, as well as movement, balance, and pulmonary capacity and can link with electronic health records to provide a comprehensive picture of individuals’ brain health.
Linus Health Raises $55M in Series B Funding
Linus Health, a Boston, MA-based digital health company focused on improving brain health, raised $55m in Series B funding
uLab Systems Raises $54.5M in Series E Financing
uLab Systems, a San Mateo, Calif.-based orthodontic startup, raised $54.5m in Series E financing.
The round included participation from existing investors along with a syndicate of orthodontists.
The company will use the funds to further advance its commercial roll out and development of its platform, which features AI-assisted treatment planning, rapid aligner delivery, the ability to plan for brackets and aligners in the same case, and customized packaging.
Led by Amir Abolfathi, CEO, uLab Systems provides digital treatment planning software and aligner products that let orthodontists take back control of their treatment plans.
uLab Systems Raises $54.5M in Series E Financing
uLab Systems, a San Mateo, Calif.-based orthodontic startup, raised $54.5m in Series E financing
Tioga Medical Raises $30M in Series B Funding
Tioga Medical, a Campbell CA-based Shifamed portfolio company that develops a valve replacement solution for mitral and tricuspid applications, raised $30M in Series B funding.
The round was led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors.
The company intends to use the funds to advance product development, support pre-clinical testing, and initiate clinical experience for its transcatheter valve replacement technology.
Led by Mike Dineen, President and CEO, Tioga is focused on providing valve replacement solutions for mitral and tricuspid applications that are procedurally symple and use a less invasive, transcatheter approach.
Tioga Medical Raises $30M in Series B Funding - FinSMEs
Tioga Medical, a Campbell CA-based Shifamed portfolio company that develops a valve replacement solution for mitral and tricuspid applications, raised $30M in Series B funding
Blues Wireless Raises $22M in Series A Funding
Blues Wireless, a Boston, MA-based provider of embedded cellular solutions, raised $22m in Series A funding.
The round was led by Sequoia Capital and Lachy Groom, with participation from XYZ Venture Capital and returning investor Bill Gates.
The company intends to use the funds to expand its global marketing, sales, and operations, and further invest in R&D for hardware and associated services to integrate data into cloud applications.
Founded in 2019 by Ray Ozzie, CEO, Blues Wireless is the creator of Notecard, a way to add wireless connectivity to any product. Notecard is a secure system on a module (SoM) with embedded 10-year global connectivity that allows any developer to send data from remote assets using JSON and just two-lines of code. The data is routed to the cloud applications of customers’ choice, again using JSON and REST. Customers represent companies spanning agriculture, automotive, construction, healthcare, industrial, manufacturing, retail, supply chain, cold chain, transportation, and logistics. Use cases range from simple tracking and remote monitoring to edge analytics and remote control.
